Acetylation polymorphism and leprosy

Area of Science:

• Pharmacogenetics
• Clinical Pharmacology
• Medical Genetics

Background:

• Sulfone drugs, particularly dapsone, are primary treatments for leprosy.
• Dapsone metabolism involves hepatic N-acetyl transferase (NAT), an enzyme exhibiting genetic polymorphism.
• Understanding acetylator phenotypes is crucial for optimizing leprosy therapy.

Purpose of the Study:

• To determine the incidence of acetylator phenotypes in leprosy patients.
• To evaluate the association between acetylator phenotype and leprosy.
• To inform more rational and effective leprosy treatment strategies.

Main Methods:

• Analysis of acetylsulfamethazine levels in urine and serum samples.
• Classification of individuals into 'rapid' and 'slow' acetylator phenotypes based on bimodal distribution.
• Statistical comparison of acetylator phenotype incidence between leprosy patients and control subjects.

Main Results:

• Bimodal distribution of acetylsulfamethazine percentages confirmed genetic polymorphism in both leprosy patients and controls.
• The slow acetylator phenotype incidence was approximately 51% in the leprosy population.
• While leprosy patients with the slow acetylator phenotype showed significantly higher SMZ acetylation, no statistical association with leprosy was found.

Conclusions:

• The slow acetylator phenotype is prevalent in the studied leprosy population.
• Despite higher SMZ acetylation in slow acetylators with leprosy, this phenotype is not directly associated with the disease.
• Further research may explore the implications of NAT polymorphism for dapsone efficacy and safety in leprosy management.